School of Medicine
Showing 1-10 of 11 Results
Postdoctoral Scholar, Pulmonary and Critical Care Medicine
BioMy long-term goal as a physician-scientist is to develop therapeutic strategies for right heart failure by elucidating its pathophysiology.
I graduated from Kyushu University, School of Medicine in Fukuoka, Japan in 2008. Following a residency program at Aso Iizuka Hospital, I finished fellowship in Emergency Medicine (1 year) and Cardiovascular Medicine (2 years). My clinical expertise is general cardiology, cardiac catheterization, echocardiography, and cardiac critical care.
After my clinical training, I started my research career working towards a Ph.D. under the mentorship of Dr. Kensuke Egashira. During my Ph.D., I published two papers focusing on the development of novel therapeutics for acute myocardial infarction and pulmonary arterial hypertension. Through this research experience, I developed skills in modeling and assessing cardiovascular disease in both small (rodents) and large animals (pigs)
In 2017, I was appointed as an Assistant Professor and attending physician in the Department of Emergency and Critical Care Medicine at Kyushu University Hospital. During this period, I learned that right heart failure was one of the most devastating conditions with no treatment options in patients with pulmonary hypertension, congenital heart disease, and patients on long-term mechanical ventricular assist devices. I also continued my research with a research grant funded by the Japanese Society for the Promotion of Science.
In 2019, I decided to further expand my research field into right heart failure and joined Dr. Edda Spiekerkoetter’s lab at Stanford University as a postdoctoral fellow. I am currently focusing on the role of BMPR2 in the cardiomyocytes, the structural changes in the right ventricle under pressure overload, and the development of right ventricle-targeting therapy in pulmonary hypertension.
Postdoctoral Scholar, Cardiovascular Medicine
BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.
Postdoctoral Scholar, Ophthalmology
BioDr. Imventarza is an M.D. from Argentina and a scientist who is dedicated to making basic discoveries and improving vision care and treatment of patients. Dr. Imventarza received his M.D. degree from CEMIC University in Buenos Aires, Argentina.
Shortly after, he initiated his ophthalmology residency at Escobar Eye Clinic. After completing residency, Imventarza completed the Argentine Society of Ophthalmology board examination, becoming a specialized ophthalmologist. He is trained in clinical consultations and surgical practices. He was an instructor for resident physicians and ophthalmic physicians in the clinical and surgical field.
Dr. Imventarza joined Dr. Liao's lab in May 2021 to learn new research techniques and to conduct rigorous scientific research in order to improve designing feasible experiments that are relevant to human disease.
The major areas of research is the understanding and treatment of human conditions that lead to retinal ganglion cell loss and irreversible thinning of the optic nerve.
Dr. Imventarza uses animal model to study what happens to the optic nerve, retina, and brain.
Dr. Alexander Ioannidis
Adjunct Professor, Institute for Computational and Mathematical Engineering (ICME)
Postdoctoral Scholar, Biomedical Data Sciences
BioDr. Alexander Ioannidis (PhD, MPhil) earned his Ph.D. from Stanford University in Computational and Mathematical Engineering, where he teaches machine learning and data science as an Adjunct Professor in the School of Engineering. He also has an M.S. in Mgmt. Sci. and Eng. (Optimization) from Stanford. Prior to Stanford, he worked in superconducting computing logic and quantum computing at Northrop Grumman. He graduated summa cum laude from Harvard University in Chemistry and Physics and earned an M.Phil in Computational Biology and Diploma in Greek from the University of Cambridge. As a current research fellow in the Stanford School of Medicine (Department of Biomedical Data Science), his work focuses on applying computational methods to problems in genomics, medical data science, and population genetics.
I work on novel algorithm design (particularly ancestry related) for several large-scale genomic studies that aim at understanding genetic causes of disease.
I also focus on projects at the intersection of history and population genetics, including work with native communities. As the grandson of Cappadocian refugees expelled from their native land, I try to engage with the complex sentiments of displaced indigenous peoples in these projects. Pain over the disruption of community heritage and over dispossession from traditional sites often remains raw. If engagement with descendant communities is lacking, research into our past can often feel like a continuation, even a legitimation, of dispossession. Combined alongside a dialogue with native communities, however, genetics can play a small role in helping to reclaim ancestral stories and dispersed ancestral connections. I hope our work in this area plays a constructive role in that process.
As written by the poet Rumi in the language of the Cappadocians (Rûm),
پیمی تیِ پَاثیِسْ پیمی تی خاسِس
“Tell me what happened to you, tell me what you have lost.”
[Rumi; Konya ms 67; translit. πε με τι έπαθες, πε με τι έχασες]